Terveystalo (TTALO) Q3 2024 earnings summary

Executive summary

• Strong earnings growth in Q3 2024 driven by improved operational efficiency, robust Healthcare Services performance, and a successful profit improvement program.

• Portfolio Business profitability improved, reflected in higher EBITA margin; Swedish business turnaround progressing as planned.

• Profitability target achieved one year ahead of schedule; quality and customer satisfaction remain high.

• Healthcare Services segment delivered its sixth consecutive quarter of strong performance, with revenue up 10.8% and adjusted EBITA up 66.6%.

• Swedish operations saw revenue fall 9.7% and profitability decline, but a profit improvement program is underway.

Financial highlights

• Q3 2024 revenue €295.8m, up 5.4% year-over-year; adjusted EBITA €34.3m, up 62.2% year-over-year; margin 11.6%.

• Q3 EPS €0.12, quadrupling year-over-year; operating cash flow €41.3m, up 16.0% year-over-year.

• Q3 net income €14.7m (vs. €3.3m); 9M net income €52.7m (vs. €21.9m).

• Net debt €545.4m (down from €597.2m); net debt/adjusted EBITDA 2.3x.

• Cash and cash equivalents: €53.4m (vs. €35.4m).

Outlook and guidance

• 2024 revenue expected to grow (2023: €1,286m); adjusted EBITA margin guided at 12–12.5% (2023: 9.8%).

• Guidance narrowed based on Q3 projections for inflation, consumer demand, employment, and normal morbidity.

• Sweden segment revenue expected to decline due to macro weakness; VAT and salary increases factored into estimates.

• No material acquisitions or divestments included in outlook.

• Estimates include VAT and salary increases, but exclude material M&A.